According to the American Congress of Obstetricians and Gynecologists (ACOG) practice bulletin, 1 estimated fetal growth below the 10th percentile for gestational age (GA) is intrauterine growth restriction (IUGR), and standards based on birth weight refer to small for gestational age (SGA). IUGR is "one of the most common and complex problems in modern obstetrics." 1 It is linked with low Apgar scores and umbilical arterial pH <7.00; admission to a neonatal intensive care unit and sepsis; increased stillbirth and neonatal mortality risks; learning difficulties and adultonset cardiovascular disease. 1 There is an imperative to prenatally identify growth restricted fetuses because, according to the practice bulletin, the neonatal mortality among detected newborns with birth weight <10th percentile for GA is 8/1000 births compared with 21/1000 births for undetected newborns. The current recommendations for identification of growth-restricted fetuses are to obtain third-trimester sonographic estimates of fetal weight (SEFWs) in high-risk pregnancies and to perform serial fundal height measurement in low-risk pregnancies at each clinic visit. Among lowrisk pregnancies, SEFWs should be reserved if there is lagging fundal height or no change in fundal height between examinations.
versus 6.9%, respectively; relative risk 0.67; 95% confidence intervals 0.50, 0.89) compared with those followed with fundal height measurements alone. The investigators concluded that although the two sonographic examinations and inductions for abnormalities noted with them increased interventions, they significantly reduced the risk of suboptimal growth. Currently the ACOG practice bulletins on IUGR 1 and on ultrasonography in pregnancy 3 do not recommend screening uncomplicated women with additional sonograms to assess fetal growth after 30 weeks.
One explanation for the lack of a recommendation in the bulletins for SEFW in low-risk women is that it does not meet the criteria for screening. As noted by Rouse et al, 4 as well as
Grimes and Schulz, 5 inappropriate screening can lead to unnecessary obstetric intervention and harm. The purpose of this commentary is to determine whether sonographic examinations in the third trimester meet the criteria for screening tests.
Criteria for Screening Tests
We identified 15 characteristics for a useful screening test (►Table 1). Fourth, the natural history should be known. ACOG has identified 33 risk factors, which are categorized as 24 arising from maternal causes, six placental and three with fetal origins. 1 The understanding of IUGR due to uteroplacental insufficiency is that cytotrophoblast invasion is shallow and endovascular invasion is rudimentary in placental development leading to poor perfusion. Morphologic placental studies have noted that the mean surface area as well as the capillary surface area is reduced. Results of cordocentesis reveal that pregnancies complicated by IUGR have fetal hypoxemia, acidosis, hypoglycemia, α-amino nitrogen, and especially branched chain amino acids. 9 Reduced urinary output is associated with oligohydramnios, which in turn is linked with cord compressions and stillbirth. 1 Long-term adverse outcomes in these babies are purported to be due fetal programming to adapt to the intrauterine environment, which lead to maladaptation.
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Fifth, an effective intervention must exist. As noted by ACOG, the following interventions do not decrease the likelihood of suboptimal growth: nutrient treatment, zinc or calcium supplementation, plasma volume expansion, maternal oxygen therapy, antihypertensive medications, and heparin or aspirin therapy. Though IUGR is unpreventable, the associated morbidity and mortality can be ameliorated. Antepartum testing with appropriate interventions lowers mortality. 
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The sixth criterion is that the screening test must be costeffective. A PubMed search, using combinations of the terms "cost effective," "intrauterine growth restriction," "small for gestational age," and "estimate fetal weight," identified a paucity of publications on the cost-effectiveness of screening for growth restriction. Such an analysis seems daunting because growth restriction is associated with both stillbirth 1 and hypoxic ischemic injuries, 14 which are leading causes of obstetric litigation. 15 It is noteworthy that Gilbert and Danielsen 16 reported that with newborns delivered at 30 to 41 weeks, the hospital charges for growth-restricted newborns are significantly higher than for those with adequate growth. This does not assure that screening for suboptimal growth will be cost-effective but suggests it might be. Seventh, facilities must be readily available to diagnose the disease. When the clinical estimate is <2500 g or if the GA is <37 weeks, then clinical estimate is not as reliable as SEFW.
17
Factors that make fundal height assessment difficult may include maternal obesity 18 as well as the inability to determine if AC is <10% for GA, a criteria for IUGR. 1 SEFW can identify IUGR and those measurements are most accurate when done by registered diagnostic medical sonographers, rather than residents, obstetricians, or maternal fetal medicine subspecialists. 19, 20 Although detection of anomalies is optimum at tertiary centers, 21 there is no suggestion that SEFW should be done solely at these centers. 20 According to the national vital statistics reports, 67% of women with live births had sonographic examinations during their pregnancy. 22 Thus, it seems that there are facilities available to do sonographic examinations and diagnose the disease. The eighth criterion of a valuable screening test is that facilities for treatment should be available. When IUGR is detected then antepartum testing should be initiated.
readily available. Administration of corticosteroids and transfer to a tertiary care facility are accepted effective treatment for spontaneous preterm labor, 24 and they should be equally efficacious for indicated preterm delivery secondary to IUGR and comorbidities like absent or reverse end diastolic flow in the umbilical artery.
13
The screening test must do its job is the ninth criterion. According to the guidelines established by the Evidence-Based 32 But a meta-analysis of nine RCTs comparing routine versus selective ultrasound in early pregnancy noted that there was no significant difference in the two groups with regards to low Apgar scores, low birth weight, admission to a neonatal intensive unit, corrected (excluding anomalies) perinatal mortality, and neurodevelopmental outcomes such as poor reading, dyslexia, or hearing defect.
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It is significant that the World Health Organization Ethics Review Board has approved a multicountry prospective study on fetal growth with seven serial ultrasound exams during pregnancy. This decision was based on a meta-analysis of 41 reports that concluded that sonographic examinations during pregnancy are not associated with adverse maternal or perinatal effects, impaired physical or neurological development, increased risk s of malignancies in childhood, or subnormal intellectual performance.
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The 11th criterion for a screening test is that it must have a reasonable and well-defined cutoff level. According to ACOG and RCOG, AC or estimated fetal weight <10% for GA 1,13 is consistent with IUGR. A recent report confirmed that these cutoffs do identify pregnancies that are at significant risk for oligohydramnios, cesarean delivery for nonreassuring fetal heart rate, admission to a neonatal intensive care unit, and newborns with an actual birth weight <10% for GA. 35 reduce the rate of SGA, it lacked sufficient sample size to show improvement in longevity, which the authors acknowledged. They calculated that 30,000 women would need to be randomized for a trial to have sufficient power to detect a 30% reduction in perinatal mortality rates between the two groups. Before such a large RCT is undertaken, we suggest a multicenter randomized trial with a composite morbidity as the primary outcome defined as, at least one of the following: admission to a neonatal intensive care unit for at least 48 hours, hypoglycemia, thrombocytopenia at term, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage (grades III or IV), sepsis, or perinatal death (stillbirth after randomization or death before newborn's discharge from the hospital). The inclusion and exclusion criteria for the proposed randomized trial are listed in ►Table 2. As with the protocol utilized by McKenna et al, 2 the expectant management group will have sonographic examination in the third trimester if there is clinical suspicion for fetal growth or amniotic fluid abnormalities, decreased fetal movements, or other obstetric indications like preterm labor or hypertensive disease. The intervention group will have sonographic examinations, evaluating fetal growth and amniotic fluid, at 30 to 32 weeks and at 36 to 37 weeks. In both groups, indications for delivery at 37 to 39 weeks will include abnormalities of amniotic fluid (oligohydramnios or hydramnios), or IUGR. Considering the vagaries of SEFW 20 and that all of the women in the trial are uncomplicated, it is possible that many of newborns suspected of being growth restricted will not be, leading to unnecessary induction and iatrogenic neonatal morbidity. These theoretical concerns are valid, but it is noteworthy that in the randomized trial by McKenna and colleagues, 2 the rate of SGA was decreased significantly, without concomitant increase in induction rate or admission to neonatal intensive care unit, a surrogate for neonatal morbidity. A published report 39 points out that the likelihood of combined neonatal morbidity (hypoglycemia, respiratory distress syndrome, thrombocytopenia, sepsis, intraventricular hemorrhage, and intubation) was 22% with growth restriction with otherwise uncomplicated pregnancies versus 2% among those with normal growth. Accordingly, in a population with a 10% rate of growth restriction, the overall rate of the combined neonatal morbidity is 4.1%. To have 80% power to observe a 36% decrease (from 4.1 to 2.6%) in composite perinatal morbidity, we would need 2966 patients in each group (α ¼ 0.05). Assuming a loss rate of 10%, the RCT needs to recruit 6000 uncomplicated patients. To obtain this sample size, 12,000 women need to be screened, assuming 50% of pregnancies are complicated or will decline participation.
Discussion
Compared with those with appropriate growth, the increased perinatal morbidity and mortality with growth-restricted newborns is undeniable. At least 10 interventions (bed rest, aspirin, nutrient supplements with calcium or zinc, maternal oxygenation, heparin, plasma volume expansion, calcium channel blockers, hormonal therapy, and smoking cessation) have been tried, but all have proven unsuccessful without decreasing the rate of IUGR or its associated complications.
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Now there is a CONSORT compliant RCT that unequivocally demonstrated a reduction in the rate of IUGR, with two additional sonographic examinations in the third trimester.
2
Despite the promising results, sonographic estimated fetal weight after 30 weeks is not being used as a screening test.
1
Thus, we reviewed the literature to determine what is present and lacking for it to be a successful screening test. We described 15 important characteristics of an ideal screening test. SEFW to detect IUGR meets 66% (10/15) of these criteria (►Table 1), which is reassuring. The criteria it does not meet currently, however, are worth emphasizing. A cost-effective analysis is warranted and should be done. Additional studies of IUGR in low-risk populations are needed to determine that among uncomplicated women, if SEFW can reliably identify IUGR, as it can with high-risk pregnancies. Although there are interobserver variability reports on measurements of biometric parameters, investigators should ascertain if detection of IUGR is reliable. The most important finding, however, of this review is that a multicenter RCT is warranted with the primary objective of reducing the combined morbidity linked with IUGR. A formidable concerted multicenter study that screens 12,000 women and randomizes 6000 is urgently needed. Such a study is justified, even at term. Neonatal charges to treat a growth-restricted newborn are about $16,000 more than those for a newborn with appropriate growth, and the likelihood of neonatal seizures, proven sepsis, grade III or IV intraventricular hemorrhage, and death within 28 days are significantly higher. Strategies aimed at screening growth-restricted fetuses should address the results of GRIT (Growth Restriction Intervention Trial) trial, which randomized women with "fetal compromise" to immediate versus delayed delivery. 40, 41 Of the 548 women enrolled, the likelihood of death before discharge was similar in the two groups (10% in immediate versus 9% in delayed group; odds ratio 1.1; 95% confidence interval 0.6 to 1.8). Additionally at 2 years, the overall rate of death or disability was not significantly different between the groups (19% in immediate and 16% in delayed group; adjusted odds ratio of 1.1; 95% confidence interval 0.7 to 1.8). These reports 40, 41 suggest that there may not be any benefit of screening for growth restriction, but we do not think the results are applicable to uncomplicated pregnancies. In GRIT trial, 7% 39 of women had multiple pregnancies, 36% (196) were randomized at 24 to 30 weeks, and 43% (234) had hypertension. Because the GRIT trial included preterm patients and had medical complications, we think our proposed randomized study should be undertaken.
There is evidence that impaired intrauterine growth is linked with several major diseases in adult life, like coronary heart disease, hypertension, and type 2 diabetes. The suggestion, referred to as "fetal programming," is that intrauterine environment provides stimulus or insult at a critical, sensitive period of early life, which has permanent effects on structure, physiology, and metabolism. 42, 43 Screening with sonographic examinations in the third trimester and inducing if abnormalities were noted significantly decreased the rate of newborns with suboptimal growth.
2 Thus one could speculate that such program will decrease disease in adult life, but this would need long-term follow-up of newborns, which would be a Herculean task. In summary, it may be feasible to reduce the rate of IUGR and its associated morbidity and mortality. At present, however, routine screening of uncomplicated women with sonographic estimated fetal weight in the third trimester is not recommended. An RCT and cost-effective analysis are needed before third-trimester sonographic estimate weight can be considered a successful screening test.
